{"filing":{"accession_number":"0001493152-26-028992","cik":"0001904286","ticker":"MIRA","company_name":"MIRA PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226028992/form8-k.htm"},"events":[{"id":11445,"run_id":10048,"accession_number":"0001493152-26-028992","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"MIRA Pharmaceuticals disclosed submission of a Phase 2a clinical trial protocol to the FDA for Ketamir-2, a proprietary oral NMDA receptor modulator for chemotherapy-induced peripheral neuropathy, with FDA acknowledgment of receipt. This represents a material clinical development milestone for a pharmaceutical company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A activity, impairment, or other defined event types). The advancement of a lead drug candidate through FDA regulatory stages is material to investors assessing the company's pipeline and prospects.","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-06-17","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":8036,"accession_number":"0001493152-26-028992","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"MIRA Pharmaceuticals disclosed submission of a Phase 2a clinical trial protocol to the FDA for Ketamir-2, a proprietary oral NMDA receptor modulator for chemotherapy-induced peripheral neuropathy, with FDA acknowledgment of receipt. This represents a material clinical development milestone for a pharmaceutical company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M\u0026A activity, impairment, or other defined event types). The advancement of a lead drug candidate through FDA regulatory stages is material to investors assessing the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:02:08.557711+00:00","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-06-17"}]}